Schedule TO-C

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE TO - C

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

Biosite Incorporated

(Name of Subject Company (Issuer))

Beckman Coulter, Inc.

Louisiana Acquisition Sub, Inc.

(Name of Filing Persons (Offerors))

Common Stock, par value $0.001 per Share

(Titles of Classes of Securities)

090945106

(CUSIP Number of Class of Securities)

Scott Garrett

President & CEO

Beckman Coulter, Inc.

4300 N. Harbor Boulevard

Fullerton, California 92834-3100

(714) 871-4848

(Name, address and telephone number of person authorized

to receive notices and communications on behalf of the filing person)

Copies to:

Paul D. Tosetti

Jonn R. Beeson

Cary K. Hyden

Latham & Watkins

633 W. 5^th Street, Suite 4000

Los Angeles, CA 90071

(213) 485-1234

CALCULATION OF FILING FEE


Transaction Valuation		Amount of Filing Fee
$N/A		$N/A

¨	Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.


Amount Previously Paid:	N/A	Filing Party:	N/A
Form or Registration No.	N/A	Date Filed:	N/A

x	Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

x	third-party tender offer subject to Rule 14d-1.

¨	issuer tender offer subject to Rule 13e-4.

¨	going-private transaction subject to Rule 13e-3.

¨	amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ¨

This presentation is neither an offer to purchase nor a solicitation of an offer to sell shares of Biosite. The tender offer for the shares of Biosite has not commenced. Stockholders of Biosite are urged to read the relevant tender offer documents when they become available because they will contain important information that stockholders should consider before making any decision regarding tendering their shares. At the time the offer is commenced, Beckman Coulter and its acquisition subsidiary will file tender offer materials with the U.S. Securities and Exchange Commission (SEC) and Biosite will file a Solicitation/Recommendation Statement with respect to the offer. The tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement will contain important information, which should be read carefully before any decision is made with respect to the tender offer. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of Biosite at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s web site at www.sec.gov. Free copies of these documents will also be made available from Beckman Coulter.

Beckman Coulter to Acquire

Biosite

Scott Garrett

President and CEO

March 26, 2007

These materials contain forward-looking statements, including statements regarding the

expected

effect

Beckman

Coulter’s

acquisition

Biosite

Beckman

Coulter’s

operating

margins and revenue growth, and regarding its role in advancing Beckman Coulter’s business.

These materials also contain forward–looking statements about Beckman Coulter’s and

Biosite’s

product development activities. These statements are based on current expectations,

forecasts and assumptions. Actual results could differ materially from those anticipated by

these forward-looking statements as a result of a number of factors, some of which may be

beyond Beckman Coulter’s control. Among other things, these factors include the risk that the

the acquisition will not be completed because the tender offer did not proceed as anticipated or

closing conditions to the acquisition were not satisfied. Other factors include the possibility that

the company will not be able to obtain the leverage across the installed based that is

anticipated, that the changes to infrastructure will not be realized or will cost more than

anticipated, that the anticipated expansion of the Company’s served market will not be realized,

and

that

the

Company’s

financial

results,

including

the

number

outstanding,

will

different from those anticipated when the effects on EPS, operating margins, and revenue

growth were calculated. Factors that affect the Company’s product development as well as a

further list and description of risks and uncertainties associated with Beckman Coulter’s and

Louisiana’s businesses are discussed in their reports filed with the Securities and Exchange

Commission, including each company’s most recent annual report on Form 10-K. Beckman

Coulter disclaims any intention or obligation to update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise, except as

required by law.

Forward-Looking Statements

Agenda

Transaction highlights

Beckman Coulter and Biosite

Beckman Coulter overview

Biosite overview

Combining market access and content

Offer price:

$85.00 per share in cash

Transaction value:

$1.55 billion

Financing:

Fully committed by

Morgan Stanley and Citigroup

Funding (long-term):

Convertible and term debt

Anticipated close:

Q2 2007

Conditions:

Customary regulatory

approvals and other conditions

Financial advisor:

Morgan Stanley

Legal advisor:

Latham & Watkins, LLP

Biosite Acquisition

Transaction Highlights

Creates leading position in U.S. Immunoassay market

segment, complementing established leadership

positions in U.S. Chemistry and Hematology segments

Combines extensive installed base of clinical lab systems

with a top developer of diagnostic tests

Expands Beckman Coulter’s served market to

‘near-patient testing’

and extends international reach

for Biosite

Immediately accelerates revenue growth, improves

operating margins and is expected to be accretive to

2008 GAAP earnings per share

Beckman Coulter proven track record in realizing value

from transactions

Beckman Coulter Overview

Industry leader in biomedical testing

Clinical Diagnostics

Life Science Research

Operating in 130 countries

Key customer: Hospital central laboratory

Broad product portfolio

Financial Performance:

2006 revenue: $2.53 billion

Recurring revenue stream: 76% of total revenue

Derived from sales of consumables, service revenue, and

payments on operating type leases

4.1%

5.1%

8.7%

9.4%

2002

2003

2004

2005

2006

Beckman Coulter:

Achieving Significant Growth from Consumables

10.5%

$800

$900

$1,000

$1,100

$1,200

$1,300

$1,400

Biosite Overview

Industry leader in delivering novel, high-value

biomarkers

Relationship with Beckman Coulter since 2003 in BNP

Immunoassay solutions for “near-patient”

testing

Triage

products used in >70% of U.S. hospitals

Financial Performance

2006 Revenue: $309 Million

85% of Revenue from U.S.

99% Consumables

2004-2006 Revenue CAGR: 12%

R&D largely focused on development of new, high-

value proprietary tests

Biosite’s Key Products

Products

Cardiovascular diseases

Congestive Heart Failure (BNP)

CardioProfilER

Shortness of Breath Panel

Bacterial and Parasitic

infections

TOX / Drugs of Abuse

Product pipeline includes

Acute Coronary Syndrome (MPO)

Semi-exclusive

Acute Kidney Injury (NGAL)

Exclusive in blood

Sepsis

Exclusive

Adds Immunoassay Leadership to Established

Leadership Positions in U.S. Clinical Lab Market

Chemistry: greater than 20%

Hematology: greater than 40%

Immunoassay: now

greater than 20%

All values expressed as a percentage of U.S. clinical lab market

share based on estimates provided by Boston

Biomedical Consultants

Combines Extensive Installed Base of Clinical Lab

Systems with Leading Developer of Novel Tests

MARKET

ACCESS

NOVEL

CONTENT

BEC #1 U.S. installed base

BEC leadership in immunoassay positions

BEC superior international presence

Biosite

strong near-patient testing position

Biosite

proven market development ability

BEC has novel assays: Cardiac, high-

risk

pregnancy, prenatal screening

Biosite

has novel assays: urgent-care

menu, acute kidney injury, sepsis

Biosite Expands Beckman Coulter’s

Served Market to Near-Patient Testing

Placed in more than 70% of U.S. hospitals

Ideal for Physician Office, Emergency Room and ICU

Low-to-moderate systems add breadth

Fastest and most preferred solution in segment

Position in large/university hospitals, ideal for rapid

adoption of novel assays

# 1 Chemistry and Automation vendor in the U.S.

First to market with second generation work cell(s)

Product Positions

Immunoassay Offerings

Large

Hospitals

Mid Range

Hospitals

Mid-2007

Work Cells

Near-Patient

Testing

Extends Biosite’s International Reach

United

States

53%

International

47%

United

States

85%

International

15%

Beckman Coulter

Biosite

Compelling Pipeline Addressing Unmet

Needs in High-Cost Disease States

Beckman Coulter

Biosite

FERTILITY:

$5B spent on Assisted

Reproductive Treatment:

private pay, risk-based

reimbursement

1M women annually seek

care for infertility.

Need better prognostics

SEPSIS:

$17B in U.S. hospital costs

210,000 deaths in U.S. / year

Need earlier and more effective

assessment

PRE-ECLAMPSIA:

Causes 15% of all

premature deliveries

$7B in total cost

Need for better risk stratification

schemes to prolong

low/moderate risk pregnancies

ACUTE KIDNEY INJURY:

$14B spent on ESRD

20M in U.S. have kidney

disease

Need earlier diagnosis-

before

fibrosis and progression

CARDIOVASCULAR

$400B spent on cardiovascular

disease in U.S.

1M U.S. discharges carry an

ACS-related diagnosis

Need for effective differential

diagnosis and improved risk

assessment

Expected to be Accretive to

2008 GAAP EPS

Existing Business

G&A Savings

Modest Incremental

Sales by leveraging

BEC global

infrastructure

Acquisition Interest

Intangible Amortization

Proposed

Acquisition of

Biosite

2007

Lumigen:

High-sensitivity

testing for novel

assays

2006

Agencourt

Bioscience:

Sample

Preparation for

Molecular Testing

Diagnostic

Systems Labs:

Novel

immunoassays

Hybritech:

Entry into

immunoassay tests

Sagian:

Life Science

Automation

Coulter Corp:

Entry into Cellular

products

Sanofi

Diagnostics:

First Immunoassay

System

2005

Prior to 2005

A Proven Track Record of Successfully

Integrating Acquisitions

Successful Integration

Delivers Value

Summary

Creates leading position in U.S. Immunoassay market

segment, complementing established leadership

positions in U.S. Chemistry and Hematology segments

Combines extensive installed base of clinical lab systems

with a top developer of diagnostic tests

Expands Beckman Coulter’s served market to

‘near-patient testing’

and extends international reach

for Biosite

Immediately accelerates revenue growth, improves

operating margins and is expected to be accretive to

2008 GAAP earnings per share

Beckman Coulter proven track record in realizing value

from transactions

Beckman Coulter

Dedicated to

improving patient

health and reducing

the cost of care